Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amlodipine + losartan + rosuvastatin (Hanmi Pharmaceutical)
- Development stage
- Phase 3
- Lead developer
- Hanmi Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A fixed-dose combination (FDC) therapy developed by Hanmi Pharmaceutical for the treatment of patients with comorbid hypertension and hypercholesterolemia. Marketed under the brand name Amosartan R (and known during development as HCP1306), it combines three active pharmaceutical ingredients: amlodipine (a calcium channel blocker), losartan (an angiotensin II receptor antagonist), and rosuvastatin (an HMG-CoA reductase inhibitor). Amlodipine and losartan work through complementary pathways to reduce blood pressure—by inducing peripheral vasodilation and inhibiting the renin-angiotensin-aldosterone system, respectively—while rosuvastatin lowers LDL cholesterol by inhibiting the rate-limiting enzyme in cholesterol biosynthesis. This combination is specifically designed to reduce the pill burden and improve medication adherence in patients who require simultaneous management of high blood pressure and dyslipidemia.
- Brand names
- Amosartan R
- Other names
- Amlodipine/Losartan/RosuvastatinAmlodipine camsylate/Losartan potassium/Rosuvastatin calcium
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)AGTR1 (Angiotensin II Type-1 receptor)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)LTCC (Voltage-gated calcium channel (L-type))
Beyond the preview
Go deeper on amlodipine + losartan + rosuvastatin (Hanmi Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amlodipine + losartan + rosuvastatin (Hanmi Pharmaceutical).